Segmentation by type of MSD assay services further refines the market taxonomy, highlighting distinct revenue streams. Multiplex Immunoassays dominate with an estimated 40% of service sales, leveraging the platform’s ability to quantify up to 10‑plex panels from a single sample, thereby reducing cost and sample volume. Electrochemiluminescence (ECL) Assays contribute approximately 25%, valued for their superior dynamic range and signal‑to‑noise ratio in low‑abundance target detection. Biomarker Discovery Services, encompassing target identification and validation, capture about 15% of the market, reflecting pharmaceutical firms’ reliance on MSD’s high‑throughput capabilities for early‑stage pipeline development. Custom Assay Development holds a 12% share, where client‑specific assay design and optimization address niche research needs across therapeutic areas. Clinical Validation Services, including assay transfer and regulatory support, represent the remaining 8%, essential for translating pre‑clinical findings into compliant clinical diagnostics. Together, these service types delineate the functional architecture of the MSD assay services market.